The RECAP assay was previously described as a method for assessing the HR proficiency of tumor cells by analyzing the formation of RAD51 foci after IR in the tumor cells that are in the S or G2 phase of the cell cycle (when the HR pathway is active) [24,26]. This evidence concerns the gene RAD51 and neoplasm.